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ABSTRACT
Objectives: To identify clinical, radiological and microbiological factors associated 
with the non conversion of sputum smears in new smear positive cases of pulmonary 
tuberculosis after two months of treatment and to evaluate the influence of non-smear 
conversion on treatment outcomes. 
Design: A prospective cohort study.
Setting:  Tuberculosis centre of Hôpital Jamot in Yaoundé- Cameroon  from April 2006 
to September 2007.
Subjects: A total of 413 patients were studied. 
Main outcome measures: Sputum smear status at two months of treatment, favourable 
treatment outcome (cured, treatment completed), unfavourable treatment outcome 
(death, treatment failure, default from treatment) and transferred out.
Results:  A total of 413 patients were studied; There were 234 (56.8%) males and 178 
(43.2%) females with a mean age of 33 years (range 9.80 years). Sputum smears did not  
convert in 55 (13.4%) patients at the end of two months of treatment. Logistic regression 
analysis showed that age above or equal to 40 years (OR=2.716, 95% CI:1.412- 5.223, p = 
0.003),  and a bacillary load of 3+ on pre-treatment sputum smears (OR=1.955; 95%CI: 
1.039-3.68, p=0.037) were significantly  associated with non conversion of sputum 
smears at the end of two months of treatment. Persistent positive smears at the end of 
two months of treatment were significantly associated with unfavourable treatment 
outcomes (p=0.025) especially default during the course of treatment.
Conclusion: In Yaoundé, Cameroon, non conversion of positive sputum smears in 
new patients with pulmonary tuberculosis at the end of two months of treatment is 
associated with an unfavourable outcome particularly defaulting later in the course of 
treatment. Non conversion of sputum smears at two months of treatment is significantly 
associated with age above or equal to 40 years and the presence of numerous bacilli 
(3+) on pre-treatment sputum smears. Patients with these factors who do not smear 
convert after two months of treatment should be given a fully supervised treatment 
for the entire duration of therapy so as to prevent in particular treatment default.
INTRODUCTION
The International Union Against Tuberculosis and 
Lung Disease (IUATLD) and the World Health 
Organisation (WHO), both emphasize the necessity 
of monitoring treatment by bacteriologic follow-up 
examination in sputum smear positive tuberculosis 
patients (1,2). The results of the follow-up examination 
at the end of the two month intensive phase of 
treatment determines whether the therapeutic 
regimen can be switched to the continuation phase 
or whether the patient should be given an additional 
month of intensive phase treatment. Despite the 
use of this strategy, several studies have shown 
that among sputum smear positive pulmonary 
tuberculosis patients, persistent sputum positivity at 
the end of two months of antituberculosis treatment 
can predict adverse outcomes in terms of increased 
failure and / or relapse rates as well as default from 
treatment (3-8). Knowledge of factors associated 
with persistent sputum positivity at the end of two 
months of antituberculosis therapy may therefore be 
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useful to clinicians to better manage their patients 
and improve outcomes.
 The aim of this study was to identify simple 
determinants of non conversion of sputum smears in 
new smear positive cases of pulmonary tuberculosis 
and evaluate its influence on treatment outcome in 
Yaoundé, Cameroon.
MATERIALS AND METHODS
Study setting:  The study was undertaken from April 
2006 to September 2007 at the tuberculosis centre 
of Hôpital Jamot, the sole referral and tuberculosis 
treatment facility for Yaoundé and surrounding areas. 
In this centre, a diagnosis of smear positive pulmonary 
tuberculosis is made on the basis of a suggestive 
clinical history and the presence of acid-fast bacilli 
(AFB) on at least two of the three sputum samples 
submitted on two consecutive days by the patient for 
microscopic examination after staining by the Ziehl 
Neelsen’s technique. Cultures for mycobacteria are 
hardly ever done.
 All newly diagnosed and previously untreated 
patients with sputum smear positive pulmonary 
tuberculosis are hospitalised during the intensive 
phase of treatment which lasts for two months. The 
total duration of treatment is six months. It consists 
of a two month intensive phase of daily rifampicin 
(R), isoniazid (H) pyrazinamide (Z) and ethambutol 
(E), followed by a four month continuation phase of 
daily rifampicin and isoniazid on out-patient basis. 
Treatment in the intensive phase is administered 
under direct supervision of the health personnel while 
compliance to treatment during the continuation phase 
is assessed by monthly return for drug collection.
 During the six month treatment period, the 
patient’s sputum is checked thrice for the presence or 
absence of AFB by direct microscopic examination. This 
is done at the end of the two month intensive phase and 
at the end of the fifth and sixth month of treatment. In 
patients whose sputum smears remain positive at the 
end of the two month phase of treatment, an additional 
month of intensive phase treatment is given followed 
by the continuation phase. The outcome of patients at 
the end of the six months of treatment is recorded into 
one of the following six mutually exclusive categories 
according to the IUATLD and WHO (1, 2): 
i) Cured: Treatment completed with a negative sputum 
smear in the last month of treatment and on at least 
one previous occasion; 
ii) Treatment completed: Patient who has completed 
treatment but does not meet the criteria to be 
classified as a cure or failure; 
iii) Treatment failure: Patient who is sputum 
smear positive at five months or later during 
treatment; 
iv) Died:  Patient who dies for any reason during the 
course of treatment; 
v) Defaulted: Patient whose treatment was interrupted 
for two consecutive months or more: 
vi) Transferred out: Patient who has been transferred 
to another recording and reporting unit and for 
whom treatment outcome is known.
Methods: A prospective cohort of all patients 
consecutively admitted to the centre with sputum 
smear positive and previously untreated pulmonary 
tuberculosis was studied. After obtaining informed 
consent from each patient on inclusion, information 
was got from each patient on age, sex, past history 
of BCG vaccination, associated history of diabetes 
mellitus, alcohol and tobacco use as well as the 
duration of symptoms before the diagnosis of 
pulmonary tuberculosis. An admission chest X-ray 
for each patient was reviewed and interpreted. Each 
chest radiograph was divided into six zones by eye 
and the presence or absence of parenchymal disease 
was recorded for each zone. The presence or absence 
of cavities as well as their number when present was 
also noted. A blood sample was collected from each 
patient for HIV serology testing after counselling. 
HIV antibodies were detected using two rapid tests: 
DetermineR HIV1/2 (Abbot Laboratories, Tokyo, 
Japan) and Immuno CombR II HIV1 and 2 BiSpot 
(Orgenics, Courbevoie, France). When the two tests 
were positive, the patient was considered positive for 
HIV. In case of discordant results, a confirmation test 
was carried out by the Western blot technique (New 
Lav blot Sanofi Diagnostics, Pasteur). The result of the 
sputum smear of each patient with the highest bacillary 
load of the three examined for diagnosis measured by 
the semi-quantitative method in use in tuberculosis 
control programmes (ie 1+,2+,3+) (1) was extracted 
from the medical file and recorded. Each patient was 
placed on the standard six month antituberculosis 
treatment regimen (2 RHEZ/4RH) for two months in 
hospital. At the end of this intensive phase of treatment 
a sputum smear examination was done for each one 
of them. The absence or presence of AFB on the smear 
of each patient was noted. Patients whose sputum 
smears remained positive at the end of this initial 
intensive phase of treatment were given an additional 
month of intensive phase therapy followed by a three 
month continuation phase of treatment. Patients whose 
sputum smears became negative were immediately 
switched on to the four month continuation phase of 
treatment. Sputum smears of each patient were again 
examined for AFB at the end of the fifth and sixth 
month of treatment. Outcomes of treatment for all 
patients were then recorded accordingly at the end of 
six months of therapy. Patients were defined as having 
a favourable outcome if they were declared cured or 
had completed treatment. Patients were defined as 
having an unfavourable outcome if they had failed 
therapy, defaulted or died.
Statistical analysis: In order to determine factors 
May 2009 EAST AFRICAN MEDICAL JOURNAL   221
associated with persistent positive sputum smears 
after two months of treatment, variables of patients 
with persistent positive sputum smears were compared 
to those of patients whose smears had become 
negative. Chi square or Fisher’s exact test was used to 
compare proportions. Logistic regression analysis was 
performed using variables found to be significantly 
associated with persistent positive sputum smears at 
two months of treatment to identify factors which were 
independently and significantly associated with it. The 
final treatment outcomes of patients with respect to 
their sputum smear conversion status at two months of 
treatment were compared using the chi square test.
RESULTS
A total of 436 patients were enrolled in the study. 
Twenty three (5.5%) of these 436 patients were 
excluded from analysis because they either absconded, 
died or were transferred out of the tuberculosis centre 
before the end of the two month intensive phase of 
treatment. Among the remaining 413 patients who 
completed the initial phase of treatment and had 
sputum smears controlled for the presence or absence 
of AFB, there were 234 (56.8%) males and 178 (43.2%) 
females with a mean age of 33 years (range 9-80 years). 
One hundred and twenty one (29.3%) of the total 413 
patients were HIV seropositive. Fifty five  (13.4%) of 
the 413 patients were sputum smear positive at the 
end of two months of treatment.
 Table 1 compares the socio-demographic and 
clinical characteristics of patients with and without 
persistent sputum smear positivity at the end of two 
months of treatment. Table 2 compares various chest 
radiological and microbiological aspects of patients 
with and without persistent sputum smear positivity 
at the end of two months of antituberculosis treatment. 
This univariate analysis showed that among the 
demographic and clinical factors, age above or equal 
to 40 years, the male sex, alcohol and tobacco use 
were significantly associated with persistent sputum 
smear positivity at the end of two months of treatment 
(Table 1). Among the radiological and microbiologic 
factors, chest lesions involving more than two zones 
and a bacillary load of 3+ were found to be significant, 
while a positive HIV serostatus had a borderline 
significance (Table 2). On the multivariate level 
(Table 3) including only these variables significantly 
associated with persistent sputum smear positivity 
at the end of two months of treatment on univariate 
analysis, it was found that age above or equal to 40 
years  (OR= 2.716, 95% CI; 1.412- 5.223, p = 0.003) 
and a bacillary load of 3+ on initial sputum smear 
examination (OR = 1.955; 95% CI: 1. 039-3.68 p = 
0.037) were significantly associated with it.
Table 1
Comparison of demographic and clinical characteristics of patients with and without persistent sputum positivity 
after two months of antituberculosis treatment
Characteristic Sputum status after two months of treatment  P-value 
 Negative (n=358) % Positive (n=55) %
Age (years)  
   < 40 77.7 47.3
   ≥ 40 22.3 52.7 1.9x10-6
Sex   
   Male 54.2 74.5
   Female 45.8 25.5 0.004
BCG  
   Yes 62.6 69.1
   No 37.4 30.9 0.34
Diabetes  
   Yes 02.2 0.0
   No 97.8 100.0 0.26
Alcohol use  
   Yes 30.7 58.2
   No 69.3 41.8 6.6x10-5
Tobacco use   
   Yes 22.9 41.8
   No 77.1 58.2 0.003
Delay before diagnosis 
   < 1 month 29.1 18.2
   ≥ 1 month 70.9 81.8 0.093
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Table 2
Comparison of chest radiological and microbiological aspects of patients with and without persistent sputum 
positivity after two months of antituberculosis treatment
Aspect                     Sputum status after two months of treatment  P-value 
 Negative (n = 358)   Positive (n = 55) 
 (%) (%) 
Chest X-ray lesions involving 
   ≤ 1 zone 51.4 34.5
   ≥ 2 zones 48.6 65.5 0.02
Chest X-ray showing cavities 
   Yes 61.5 67.3
   No 38.5 32.7 0.40
Chest X-ray showing 
   Single cavity 56.4 50.0
   Multiple cavities 43.6 50.0 0.47
HIV status 
   Positive 27.7 40.0
   Negative 72.3 60.0 0.06
Sputum AFB smear
   ≤ 2+ 57.3 36.4
   3+ 42.7 63.6 0.004
Table 3
 Logistic regression analysis for factors independently associated with persistent sputum positivity after two months 
of treatment
Factor β-coefficient P-value Odds ratio 95% CI
Age ≥ 40 years - 0.9992 0.003 2.716 1.412-5.223
Male sex 0.7193 0.067 2.053 0.952-4.43
Alcohol use 0.5499 0.148 1.733 0.823-3.65
Tobacco smoking -0.0460 0.910 0.955 0.431-2.12
Two or more lung zones affected 0.6659 0.104 1.945 0.871-4.35
Two or more months delay 
before diagnosis -0.2291 0.558 0.795 0.369-172
HIV negative status -0.6069 0.074 0.545 0.280-1.06
Sputum bacillary load at 
diagnosis at 3+ 0.6706 0.037 1.955 1.039-3.68
Table 4
Final treatment outcomes in patients with smear positive pulmonary tuberculosis in relation to sputum smear 
conversion status at two months (n = 413)
Final treatment outcomes  Sputum smear status after two months of treatment
                  Negative (n =358)                Positive (n = 55)  
 No.  (%)   No. (%)
Cured  251  70.1 26  47.3
Treatment completed 43  12.0 10    18.2
Treatment failure 0   00.0  01   01.8
Defaulted  54   15.1  14    25.5
Died  4   01.1 00  00.0
Transferred out  6   01.7  04   07.2
Total 358   100 55   100
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 The final treatment outcomes of the 413 patients 
with smear positive pulmonary tuberculosis in 
relation to their smear conversion status at the end 
of two months of treatment is presented in Table 4. 
Only 36 (70.6%) of the 55 patients with persistent 
positive sputum smears at the end of two months 
of treatment as compared to 294 (83.5%) of the 358 
patients with negative sputum smears (Table 5) had 
a favourable outcome (p = 0.025). 
DISCUSSION
The search for tools to monitor the treatment of 
tuberculosis patients and predict its outcome 
continues. Studies have shown that non conversion of 
positive smears at the end of two months of treatment 
is one of the strongest predictors for treatment failure 
(3-6) although it is not a very reliable indicator because 
of its low positive predictive value.
 Indeed a positive sputum smear for AFB does 
not permit one to know whether these are still viable 
bacteria or not after two months of antituberculosis 
treatment. To assess sputum sterilisation therefore, 
it is ideal to study cultures for mycobacteria at the 
end of two months, as microscopy may also show 
non viable bacilli. However under programme 
conditions, particularly in most low income countries 
like Cameroon, cultures for mycobacteria are not 
available under field conditions. Furthermore, 
conventional results of culture on media would be 
available far too late (after more than two months) 
to be useful. The correlation between sputum AFB 
smear and culture is generally good (9) although 
there are reports on the poor correlation of smear 
and culture during treatment and the unreliability 
of smear for declaration of failure (10). Studies have 
however shown that in countries where limited 
culture and sensitivity studies for mycobacteria are 
available, sputum microscopy at two months may be 
a critical determinant of high and low risk patients for 
treatment failure (3-4). Sputum smear examination 
may therefore serve as a proxy for culture examination 
in low income countries under programme conditions, 
keeping in mind its limitations. 
 In this study, non conversion of sputum 
specimens of new smear positive patients with 
pulmonary tuberculosis after two months of treatment 
was more likely to be associated with unfavourable 
outcomes in terms of treatment failure and particularly 
default from treatment. Our results are in agreement 
with those of previous studies that have shown that 
among sputum positive pulmonary tuberculosis 
patients, persistent sputum positivity at the end of the 
initial two months of treatment can predict adverse 
outcomes (3-7). The development of tools which 
can prospectively identify patients with delayed 
sputum sterilisation so that they can then be better 
managed is therefore necessary. Some techniques 
have been described (11-13) but these are still too 
sophisticated for routine use even in developed 
countries. As such, there is a need in developing 
countries particularly those of sub-Saharan Africa 
where tuberculosis is highly prevalent that simple 
predictive factors associated with non conversion 
of sputum smears after the initial two months of 
treatment be identified.
 In this study we assessed clinical, microbiological 
and radiological factors in new pulmonary 
tuberculosis patients receiving treatment under 
direct supervision by nurses in accordance with 
routine national tuberculosis control guidelines in 
a bid to identify simple factors associated with non 
conversion of positive sputum smears at the end 
of the initial two months of treatment. Univariate 
analysis of these factors showed that delays superior 
to one month before diagnosis, the presence of 
cavities on chest X-rays of patients as well as an HIV 
seropositive status were not significantly associated 
with non conversion of positive sputum smears. Of 
the factors that showed a significant relationship 
with persistent sputum positivity after two months 
of antituberculosis therapy on univariate analysis, 
only age above or equal to 40 years and numerous 
bacilli (3+) on pre-treatment sputum smears remained 
significant independent predictors on multivariate 
analysis (Table 3).
 The absence of a significant relationship between 
cavitary disease and non conversion of positive 
sputum smears after two months of treatment in our 
study is not in line with results from other reports (7-
14-15). Cavitary disease has been found by Telzac et 
al (14) to be independently associated with a greater 
Table 5
Comparison of final favourable and unfavourable treatment outcomes in 413 patients with smear positive 
pulmonary tuberculosis in relation to sputum smear conversion status at two months
Final treatment outcome  Sputum smear status after two months of treatment    
                         Negative (n = 358)          Positive (n = 55) P - value 
  No.  (%) No.  (%)
Favourable 294  83.5 36  70.6
Unfavourable  58   16.5 15   29.4 0.025
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number of days for sputum smear and culture 
conversion. Hiyama et al (15) also reported in a study 
looking at factors influencing response to treatment 
that progressive chest X-ray findings were associated 
with delayed sputum smear conversion. Finally in a 
study similar to ours, Singla et al (7) in Riyadh, Saudi 
Arabia reported that the presence of multiple cavitary 
lesions on chest X-ray were significantly associated 
with persistent sputum smear positivity.
  HIV seropositivity was not associated with the 
non conversion of positive sputum smears after two 
months of antituberculosis treatment in our study. 
Our results are in agreement with those of several 
studies which have shown that HIV positive patients 
co-infected with pulmonary tuberculosis do not 
show delayed sputum conversion (14, 16, 17). On the 
contrary it has even been argued by some authors (14) 
that HIV positive patients may instead have early 
sputum conversion. 
 Age above or equal to 40 years was an 
independent predictor of non-conversion of sputum 
smears in our smear positive pulmonary tuberculosis 
patients after the initial two months of anti tuberculosis 
chemotherapy. Singla et al (7) observed in a similar 
study that patients aged over 60 years had an almost 
six times greater risk of remaining sputum positive 
after two months of treatment than patients aged 21-
40 years, while patients aged 41-60 years were twice 
as likely to remain sputum positive. Liu et al (16) also 
reported that the elderly were the least likely to have 
documented sputum conversion after two months of 
treatment. The reason why old age should predispose 
to delayed sputum smear conversion is not exactly 
known.
 In this study, the presence of numerous bacilli (3+) 
on initial pre-treatment sputum smears was also an 
independent predictor of non conversion of positive 
sputum smears after two months of antituberculosis 
therapy. The direct influence of initial bacillary load 
on the absence of sputum conversion at  two months 
of therapy has been reported by several authors 
(3,5,7,15). Rieder (3) observed that in a refugee camp 
in Thailand, sputum conversion at the end of the two 
months of directly observed therapy among patients 
with initial weakly positive sputum was 90.9% while 
it was respectively 77.9% and 61.7% among patients 
with initial moderately positive and strongly positive 
sputum (3). However in an adjusted analysis, he 
observed that initial smear positivity was not an 
independent predictor for subsequent positivity at 
four months or later. Singla et al (7) reported that 
patients with numerous bacilli on pre-treatment 
sputum smear examination had an almost six times 
greater risk of persistent sputum positivity than 
patients with few bacilli. Meanwhile, Lienhart et al (5) 
reported sputum conversion at the end of two months 
in patients with initial sputum smear 1+,2+,3+ to be 
96.2%, 85.8%, and 81.8% respectively. They further 
reported that treatment failure was associated with 
increasing bacillary load while the absence of sputum 
smear conversion after two months was associated 
with defaulting later during treatment, a result similar 
to ours.
In conclusion, non conversion of positive sputum 
smears in new patients with pulmonary tuberculosis 
in Yaoundé, Cameroon, at the end of two months of 
treatment is associated with unfavourable treatment 
outcomes particularly defaulting later during the 
course of therapy. In this setting, non conversion 
of sputum smears after the initial two months of 
antituberculosis treatment is associated with age 
above or equal to 40 years and the presence of 
numerous bacilli (3+) on pre-treatment sputum 
smears. It is therefore recommended that patients 
with these factors who do not smear convert after 
two months of antituberculosis treatment in Yaoundé, 
be given a fully supervised treatment for the entire 
duration of chemotherapy so as to prevent in 
particular default from treatment.
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